The Selfie study: Cervical precancer detection using novel human papillomavirus biomarkers.
Abstract
10533 Background: Human papillomavirus (HPV) causes the majority of cervical cancers worldwide. Dual stain cytology can detect HPV oncogenic activity through biomarkers p16/Ki-67 in cervical samples. Dual stain is an acceptable triage strategy for HPV-positive results from clinician-collected samples, reducing the number of low-risk individuals sent for colposcopy or treatment. However, the ability of dual stain to triage self-collected vaginal specimen is poorly understood. The Selfie Study is an observational study to assess the diagnostic accuracy of different biomarkers for cervical precancer on self-collected samples. Here, we evaluated dual stain cytology in clinician and self-collected specimens for detection of cervical precancer. Methods: Individuals with a cervix ages 25-69 years undergoing cervical cancer screening, colposcopy, or treatment at George Washington University (GWU) and Sarasota Memorial Hospital (SMH) were included in this study (August 2020-August 2024). Participants were instructed to perform self-collection prior to clinician-collection during the clinic visit. Demographics and clinical outcomes of dual stain on paired cervicovaginal samples and presence of cervical intraepithelial neoplasia 2 or worse (CIN2+) were recorded and assessed using descriptive statistics. Differences in sensitivity and specificity of dual stain to detect CIN2+ between the two collection methods were assessed using McNemar’s test. Results: A total of 548 participants enrolled in Selfie. Paired dual stain results were available for 411 participants (411/548, 75%), of which 24 participants were CIN2+ (24/411, 5.8%). Missing results were due to inadequate/absent staining for one or both collection methods. Dual stain was positive in 63 clinician-collected samples (63/411, 15.3%) and in 39 (39/411, 9.5%) self-collected samples. Overall percent agreement between collection methods was 89.3% (367/411). Percent positive agreement was 39.7% (29/73). Dual stain was 83.3% (20/24) sensitive to detect CIN2+ in clinician-collected samples and 45.8% (11/24) sensitive in self-collected samples (83.3% versus 45.8%, p = 0.003). Conclusions: Dual stain on self-collected samples had significantly lower sensitivity for detection of CIN2+ compared to clinician-collected samples. Additional research is needed to evaluate whether the performance is more comparable for CIN3+ endpoints. Our study highlights the challenges of conducting triage assays from self-collected specimens. Clinical trial information: NCT04423679 .
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (5)
Sarah Phillips
Nicole Chappell
George Washington University, Washington, DC
Beverly J. Long
Sarasota Memorial Healthcare System, Sarasota, FL
Megan Clarke
National Cancer Institute, Rockville, MD
Nicolas Wentzensen
Division of Cancer Epidemiology and Genetics National Cancer Institute, National Institutes of Health Rockville Maryland USA